Supriya Lifescience reports 21.7 per cent Y-o-Y revenue increase in Q1 FY24, ET HealthWorld

Mumbai: The financial statements for the first quarter of Q1 FY 25 have been released by Supriya Lifescience Ltd, a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.

In the first quarter of FY25, the company witnessed growth in its revenue, reporting a 21.7 per cent year-over-year increase, reaching Rs 160.63 crore compared to Rs 132.02 crore in Q1 FY24. EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA margin of 38.9 per cent, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7 per cent. This marks a growth of 40.6 per cent YoY. The profit after tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24. The PAT margin stood at 27.8 per cent in Q1 FY25, compared to 21.6 per cent in Q1 FY24. The company has seen good growth across different therapeutic areas in Q1FY25. European markets now contribute 51 per cent of the company’s business revenue up from 43 per cent in Q4FY24 and 34 per cent in Q1FY24.

Dr Saloni Wagh, Managing Director, Supriya Lifescience Ltd, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs 146 crore in the last financial year while also enhancing its return on equity by 210 basis points

We’re proud to unveil our new R&D facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.”